Table 2.
Treatment features and supportive care. Characteristics of regimens, dose, duration, and concomitant medications for prophylaxis of treatment-related infections and cytopenias.
| Characteristic (n. of Analyzed Patients) * | n. (%) |
|---|---|
| Bendamustine containing regimen (%) | |
| Bendamustine ± antiCD20 | 146 (81.6) |
| BEGEV | 6 (3.4) |
| BAC | 13 (7.3) |
| Other | 14 (7.8) |
| Bendamustine dose (%) (173) | |
| 90 mg/m2 | 106 (61.3) |
| 70 mg/m2 | 58 (33.5) |
| <70 mg/m2 | 9 (5.2) |
| Anti-CD20 monoclonal antibody (%) | |
| No | 17 (9.5) |
| Rituximab | 160 (89.4) |
| Obinutuzumab | 2 (1.1) |
| N. of completed cycles (%) | |
| <4 | 28 (15.7) |
| At least 4 | 150 (84.3) |
| Up to 6 | 120 (67.4) |
| Therapy interruption (%) | |
| No | 142 (79.3) |
| Yes | 37 (20.7) |
| Dose delay (%) (177) | |
| No | 112 (63.3) |
| Yes (at least 1 week delay) | 65 (36.7) |
| Dose reduction (%) (178) | |
| No | 155 (87.1) |
| Yes | 23 (12.9) |
| G-CSF prophylaxis (%) | |
| No | 102 (57.0) |
| Yes | 77 (43.0) |
| Erythropoietin prophylaxis (%) (177) | |
| No | 148 (83.6) |
| Yes | 29 (16.4) |
| Trimethoprim-sulfamethoxazole prophylaxis (%) (177) | |
| No | 31 (17.5) |
| Yes | 146 (82.5) |
| Acyclovir prophylaxis (%) (177) | |
| No | 105 (59.3) |
| Yes | 72 (40.7) |
* Number of analyzed patients is shown where different from total numbers of patients.